MX2016012052A - Dimetilfumarato y regimenes de vacunacion. - Google Patents
Dimetilfumarato y regimenes de vacunacion.Info
- Publication number
- MX2016012052A MX2016012052A MX2016012052A MX2016012052A MX2016012052A MX 2016012052 A MX2016012052 A MX 2016012052A MX 2016012052 A MX2016012052 A MX 2016012052A MX 2016012052 A MX2016012052 A MX 2016012052A MX 2016012052 A MX2016012052 A MX 2016012052A
- Authority
- MX
- Mexico
- Prior art keywords
- dimethyl fumarate
- subject
- vaccination regimens
- administering
- dose
- Prior art date
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title abstract 2
- 229960004419 dimethyl fumarate Drugs 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se provee un método de tratamiento o prevención de una enfermedad o trastorno (por ejemplo, esclerosis múltiple) en un sujeto en necesidad del mismo, que comprende: (a) administrarle al sujeto una primera dosis de una composición farmacéutica que comprende un agente de fumarato (por ejemplo, fumarato de dimetilo) durante un primer periodo de dosificación; (b) administrarle una vacuna; y (c) administrarle al sujeto una segunda dosis de la composición farmacéutica durante un segundo periodo de dosificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953259P | 2014-03-14 | 2014-03-14 | |
| PCT/US2015/020470 WO2015138917A1 (en) | 2014-03-14 | 2015-03-13 | Dimethyl fumarate and vaccination regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016012052A true MX2016012052A (es) | 2017-04-27 |
| MX389474B MX389474B (es) | 2025-03-20 |
Family
ID=52737422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012052A MX389474B (es) | 2014-03-14 | 2015-03-13 | Dimetilfumarato y regimenes de vacunacion. |
| MX2022000746A MX2022000746A (es) | 2014-03-14 | 2016-09-14 | Dimetilfumarato y regimenes de vacunacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000746A MX2022000746A (es) | 2014-03-14 | 2016-09-14 | Dimetilfumarato y regimenes de vacunacion. |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10391160B2 (es) |
| EP (2) | EP3116536A1 (es) |
| CA (1) | CA2942690A1 (es) |
| MA (2) | MA51730A (es) |
| MX (2) | MX389474B (es) |
| WO (1) | WO2015138917A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2942690A1 (en) | 2014-03-14 | 2015-09-17 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| WO2016090154A1 (en) * | 2014-12-04 | 2016-06-09 | Biogen Ma Inc. | Multiple sclerosis treatment regimen using dimethyl fumarate |
| CA3182369A1 (en) * | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| WO2021252915A1 (en) * | 2020-06-11 | 2021-12-16 | University Of Massachusetts | Gasdermin d (gsdmd) succination for the treatment of inflammatory disease |
| WO2022204259A1 (en) * | 2021-03-25 | 2022-09-29 | The Regents Of The University Of California | Compositions and methods for inhibiting and treating viral infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| PL2801355T3 (pl) | 2004-10-08 | 2015-10-30 | Fwp Ip Aps | Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego |
| SG11201404705YA (en) | 2012-02-07 | 2014-10-30 | Biogen Idec Inc | Pharmaceutical compositions containing dimethyl fumarate |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| WO2015130998A1 (en) | 2014-02-28 | 2015-09-03 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| CA2942690A1 (en) | 2014-03-14 | 2015-09-17 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
| AU2015328676B2 (en) | 2014-10-08 | 2017-07-20 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| WO2017040272A1 (en) | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| WO2017151184A1 (en) | 2016-02-29 | 2017-09-08 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10523918B2 (en) | 2017-03-24 | 2019-12-31 | Samsung Electronics Co., Ltd. | System and method for depth map |
-
2015
- 2015-03-13 CA CA2942690A patent/CA2942690A1/en active Pending
- 2015-03-13 MX MX2016012052A patent/MX389474B/es unknown
- 2015-03-13 EP EP15712240.9A patent/EP3116536A1/en not_active Ceased
- 2015-03-13 WO PCT/US2015/020470 patent/WO2015138917A1/en not_active Ceased
- 2015-03-13 EP EP19199534.9A patent/EP3650042A1/en not_active Withdrawn
- 2015-03-13 MA MA051730A patent/MA51730A/fr unknown
- 2015-03-13 US US15/125,612 patent/US10391160B2/en active Active
- 2015-03-13 MA MA039743A patent/MA39743A/fr unknown
-
2016
- 2016-09-14 MX MX2022000746A patent/MX2022000746A/es unknown
-
2019
- 2019-04-23 US US16/391,583 patent/US10555993B2/en not_active Expired - Fee Related
- 2019-12-30 US US16/729,710 patent/US10994003B2/en not_active Expired - Fee Related
-
2021
- 2021-04-12 US US17/228,004 patent/US20210228701A1/en not_active Abandoned
- 2021-11-17 US US17/528,844 patent/US20220072117A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2942690A1 (en) | 2015-09-17 |
| EP3116536A1 (en) | 2017-01-18 |
| US20190247485A1 (en) | 2019-08-15 |
| MX2022000746A (es) | 2022-02-14 |
| US20170000873A1 (en) | 2017-01-05 |
| US20210228701A1 (en) | 2021-07-29 |
| MA39743A (fr) | 2017-01-18 |
| US20220072117A1 (en) | 2022-03-10 |
| MA51730A (fr) | 2020-12-16 |
| EP3650042A1 (en) | 2020-05-13 |
| MX389474B (es) | 2025-03-20 |
| US10391160B2 (en) | 2019-08-27 |
| WO2015138917A1 (en) | 2015-09-17 |
| US10555993B2 (en) | 2020-02-11 |
| US20200360501A1 (en) | 2020-11-19 |
| US10994003B2 (en) | 2021-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2016012052A (es) | Dimetilfumarato y regimenes de vacunacion. | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
| GT201700280A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CO2017007383A2 (es) | Métodos para utilizar oligonucleótidos antisentido para smad7 | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
| MX2017005244A (es) | Regimen de dosificacion para interferon pegilado. | |
| HK1232465A1 (en) | Dimethyl fumarate and vaccination regimens | |
| CL2019001462A1 (es) | Composición mejorada de lansoprazol y simeticona y proceso para prepararla. | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
| UA98635U (ru) | Способ профилактики гипофункции родов у овец и коз и повышение жизнеспособности новорожденных ягнят и козлят с использованием препарата "карафест" | |
| PL410409A1 (pl) | Sposób różnicowania, test diagnostyczny do różnicowania szczepów szczepionkowych od szczepów terenowych wirusa wścieklizny oraz zastosowanie testu diagnostycznego | |
| UA97125U (uk) | Спосіб немедикаментозного лікування, реабілітації та профілактики із застосуванням дельфінів |